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Despite the multifactorial nature of the ontogeny of drug clear-
ance, pediatric population models describe net observed 
changes in ontogeny with a limited number of covariate rela-
tionships. Therefore, these models are only applicable to spe-
cific drugs in a specified population, requiring collection and full 
analysis of the same type of data for every drug in every popula-
tion. Physiologically based (PB) pharmacokinetic (PK) models 
use in vitro data on drug kinetics in combination with anatomi-
cal measurements and physiological parameters to quantify 
physiological processes and the interaction of a molecule with 
certain physicochemical properties with this system. The sys-
tem-specific parameters in PBPK models are not restricted to 
specific drugs, making these models more generalizable and 
useful for selecting first-in-child doses for new compounds in 
drug development. Only rarely has PBPK modeling, known 
as “bottom–up approach”, been combined with population PK 
modeling, known as “top–down approach”, to augment each 
other in a semiphysiological “middle out approach”.
Previous studies on the UGT2B7-mediated glucuronida-
tion of morphine and zidovudine (see Part I of this article, 
ref. 1) and the glomerular filtration of antibiotics2 suggest that 
pediatric population covariate models for clearance contain 
biological system-specific rather than drug-specific informa-
tion and that this system-specific information can be extrapo-
lated between drugs that share elimination pathways. In such 
semiphysiological PK modeling approaches, the ease of 
analyzing outcome measures with population PK modeling is 
combined with the mechanistic insight of PBPK modeling.
In this study, the physiological and physicochemical basis 
of the semiphysiological covariate function for UGT2B7-
mediated glucuronidation in children younger than 3 years 
(see Part I of this article, ref. 1) is investigated. To define 
preconditions for the use of this semiphysiological func-
tion, the influence of system- and drug-specific parameters 
on the net maturation pattern of in vivo UGT2B7-mediated 
glucuronidation was investigated. This information is used to 
identify both patient and drug characteristics that potentially 
limit the applicability of the semiphysiological glucuronida-
tion function. In addition, the results obtained can be used to 
establish the information that can be provided by population 
pediatric covariate models for maturation functions of elimi-
nation pathways in PBPK models.
RESULTS
System-specific parameters
Table 1 presents the changes in parameter values of liver 
blood flow, liver volume, milligram protein per gram of liver, 
UGT2B7 ontogeny, and unbound drug fraction in the first 3 
years of life according to the pediatric PBPK model in Simcyp 
in five age-categories. In addition, the sensitivity of in vivo 
clearance to these changes is quantified as a sensitivity 
ratio, with a ratio of 0.80 indicating that a 10% increase in 
the parameter value would increase clearance by 8%. Finally, 
the percentage change in in vivo clearance as a result of 
the changes in the underlying system-specific parameters is 
presented. It is shown that the contribution of each system-
 specific parameter to the developmental changes in clear-
ance is different for morphine and zidovudine. With respect to 
the different age groups, the contribution of the parameters 
to developmental changes in clearance is highly nonlinear 
and may even be bidirectional. Despite this, liver volume 
can overall be regarded as the main driver of developmental 
changes in UGT2B7-mediated glucuronidation, causing an 
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increase in clearance in the different age groups between 
13 and 31% for morphine and 7.3 and 22% for zidovudine, 
with an especially large contribution in the first 3 months of 
life. The increase in morphine and zidovudine clearance as a 
result of UGT2B7 ontogeny in the different age groups ranges 
between 10 and 29% and 7.4 and 18%, respectively. The 
influence of hepatic blood flow on developmental changes 
in morphine  clearance is <5% in all age groups and can be 
regarded n egligible, whereas for zidovudine, the contribution 
of changes in hepatic blood flow to increases in clearance 
ranges between 3.7 and 7.9%. For both drugs, the contri-
bution of changes in milligram protein per gram of liver and 
unbound drug fraction is negligible in all age groups.
Drug-specific parameters
Simulations with hypothetical small-molecular UGT2B7 sub-
strates (Table 2) revealed that the physicochemical drug 
properties such as molecular weight, octanol/water partition 
coefficient (log P), and acid dissociation constant (pK
a
) do not 
influence the ontogeny profile of in vivo UGT2B7-medidated 
glucuronidation. Assuming that the changes in mass did not 
alter the uptake or efflux by hepatocytes or the interaction 
with the UGT2B7 isoenzyme, molecular mass in the range 
between 100 and 1,000 g/mol did not influence this clearance 
at all. Increasing log P between 0.01 and 5.5 yielded a slight 
decreasing trend in the predicted clearance, whereas increas-
ing the pK
a
 between 2 and 12 yielded an increasing trend in 
predicted clearance. No strong relationship was observed 
between the physicochemical properties of the hypothetical 
drugs and the clearance, nor was there a relationship between 
the derived blood to plasma ratio and clearance. There was, 
however, a strong linear correlation (r = 0.978) between the 
clearance predicted by the PBPK model and the unbound 
drug fraction of the hypothetical drug in plasma, which was 
derived from the log P and pK
a
 value using the Simcyp toolbox. 
According to this relationship, every 0.1 increase in unbound 
Table 1 System-specific parameters investigated in this study. The percentage increase in parameter value in each of the five age groups (I–V) and the mean 
sensitivity ratios of the clearance of morphine and zidovudine in each group is provided. The calculated percentage change in in vivo morphine and zidovudine 
clearance as a result of the change in the underlying system-specific parameters are also presented
System-specific model parameter
Developmental change in  
parameter value for each  
age group according to the  
physiologically based model
Mean sensitivity ratioa of in vivo 
drug clearance to the changes 
in the model parameters for each 
age group
Mean net change in in vivo  
clearance as a result of  
developmental changes in   
parameters for each age group
Morphine Zidovudine Morphine Zidovudine
Liver volume     I:    38%   I:     0.82   I:    0.58   I:  31%   I:  22%
    II:  18%   II:    0.81   II:  0.56   II:    15%   II:    10%
    III: 19%   III: 0.79   III:   0.50   III:  15%   III:   9.5%
    IV: 17%   IV:    0.76   IV:  0.43   IV: 13%   IV: 7.3%
     V: 21%   V:   0.72   V:     0.35   V:    15%   V: 7.4%
UGT2B7 ontogeny     I: 12.7%   I:   0.90   I:    0.66   I:   11%   I:    8.4%
    II:  11.4%   II:    0.90   II:  0.65   II:    10%   II:  7.4%
    III:   20.2%   III:    0.88   III:   0.60   III:  18%   III:  12%
    IV: 33.8%   IV:    0.85   IV: 0.52   IV: 29%   IV: 18%
      V:    25.2%   V:   0.81   V:  0.45   V:    20%   V:   11%
Hepatic blood flow     I:    33%   I:    0.059   I:  0.24   I:    1.9%   I:    7.9%
    II: 17%   II:   0.061   II:  0.22   II:  1.0%   II:  3.7%
    III: 19%   III: 0.081   III:   0.29   III: 1.5%   III:   5.5%
    IV: 22%   IV: 0.103   IV: 0.22   IV: 2.3%   IV: 4.8%
    V: 24%   V: 0.127   V:     0.29   V: 3.0%   V: 7.0%
Milligram microsomal protein per gram 
of liver
    I:   0.71%   I:  0.83   I:    0.62   I:    0.6%   I:    0.4%
    II: 0.70%   II:   0.83   II:  0.60   II:    0.6%   II:  0.4%
    III: 1.63%   III: 0.81   III:   0.55   III:   1.3%   III: 0.9%
    IV:   3.3%   IV:    0.78   IV: 0.47   IV: 2.6%   IV: 1.6%
    V:   3.1%   V:  0.75   V:  0.39   V: 2.3%   V: 1.2%
Unbound drug fraction Morphine Zidovudine
  I:     −1.6%  I:  −0.93%     I: 0.92   I:  0.71  I:  −1.5%  I:    −0.66%
  II:     −0.72%  II:  −0.45%     II: 0.92   II:  0.70  II:  −0.67%  II:   −0.32%
  III:    −1.5%  III:    −0.89%    III: 0.90   III:   0.65  III:    −1.4%  III:    −0.58%
  IV:  −0.05%  IV:−0.008%   IV: 0.87   IV: 0.58  IV: −0.04%  IV: −0.005%
  V:    1.2%  V:     0.74%      V: 0.85   V:      0.51  V:  1.02%  V:   0.38%
Age groups: I, 0–3 months; II, 3–6 months; III, 6–12 months; IV, 1–2 years; V, 2–3 years.
aSensitivity ratio, ratio of difference in in vivo drug clearance and difference in model parameter value for each individual.
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drug fraction resulted in a parallel increase in in vivo clearance 
of 1.5 l/h across the studied age range.
Semiphysiological glucuronidation function
Figure 1 shows the in vivo morphine and zidovudine clear-
ance values in children younger than 3 years obtained in 
population models using the semiphysiological glucuronida-
tion function (see Part I of this article, ref. 1 and ref. 3) and the 
PBPK model in Simcyp. The graphs indicate an underpredic-
tion of the clearances in children older than 10 days (solid 
circles) by the PBPK model, yielding a mean percentage dif-
ference for this older population of −68.3% for morphine and 
−19.1% for zidovudine. In neonates younger than 10 days 
(asterisks), the reduction in glucuronidation capacity as quan-
tified by the semiphysiological glucuronidation function is not 
observed in the predictions by the PBPK model, yielding a 
mean percentage difference of −19.4% for morphine and 
105% for zidovudine. This illustrates large differences in the 
prediction of developmental changes in in vivo glucuronida-
tion clearance between the population models with the semi-
physiological glucuronidation function and the PBPK model 
in the first 2 weeks of life. According to the bottom graphs, 
the prediction difference remains constant throughout the 
Table 2 Drug-specific parameters for morphine, zidovudine, and  
hypothetical drugs used in the physiologically based simulations
Parameter (unit)
Parameter values
Ref.Morphine Zidovudine
Hypothetical 
drug
Physicochemical parameters
Molecular mass  
(g/mol)
285.34 267.24 100–1,000
log P 0.77 0.05 0.01–5.5 33–36
pK
a1 7.93 9.68 2–12 27,31,33
pK
a2 9.63 —
Blood binding parameters
Blood/plasma ratio 1.08 0.86 Derived 36–38
Fraction unbound in 
adults
0.62 0.77 Derived 36,39,40
Enzyme kinetic parameters
K
m
 (μmol/l) 115.8 4 115.8
V
max
  
(pmol/min/mg protein)
9,250, M3G
1,166
9,250
26,27
1,917, M6G 1,917
K
m
, Michaelis–Menten constant; log P, octanol/water partition coeffi-
cient; NA, not applicable; pK
a
, acid dissociation constant; V
max
, maximum 
 formation rate.
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Figure 1 In vivo morphine clearance (top left) and zidovudine clearance (top right) vs. bodyweight in children younger than 3 years 
according to the physiologically based pharmacokinetic model (asterisk for neonates younger than 10 days, and solid dots for  children 
older than 10 days) and the population models using the semiphysiological glucuronidation function (lines are population  predictions and 
the shaded area indicates the 95% prediction interval). The difference in clearance value between the models is depicted vs. bodyweight 
for both drugs (bottom). The horizontal lines in these graphs show 0% prediction difference (solid line) and ± 30%  prediction difference 
(dotted lines) and the gray line represents the loess curve of the data.
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bodyweight range in older children, suggesting that in this 
subpopulation, the maturation profile predicted by the PBPK 
model mainly differs from the population models in absolute 
value while it is similar in shape.
Developmental changes in in vivo morphine and zidovu-
dine clearance relative to birth are depicted in Figure 2 for 
the population models using the semiphysiological glucuroni-
dation function (gray lines) and the PBPK model (black lines), 
including the individual contribution of each system-specific 
parameter in the physiologically based model (nonsolid black 
lines). It can be seen that for both drugs, the largest contribu-
tion to the increase in clearance comes from the increase in 
liver volume (dotted black line) and UGT2B7 ontogeny (long 
dashed black line). When not taking into account the rapid 
increase in drug glucuronidation in the semiphysiological 
function at 10 days after birth (dashed gray line), the com-
bined influence of the changes in the five system-specific 
parameters investigated in this study explains 79% of the 
clinically observed increases in morphine clearance and 41% 
of the clinically observed increases in zidovudine clearance 
in the first 3 years of life.
DiScUSSiOn
We have previously shown that the clinically observed mat-
uration pattern for morphine glucuronidation in children, 
who had been quantified in a pediatric population covariate 
model,3,4 could be directly extrapolated to the glucuronidation 
of zidovudine in a semiphysiological modeling approach (see 
Part I of this article, ref. 1). This study investigates the extent 
to which the semiphysiological glucuronidation function can 
be extrapolated to other patient populations or other UGT2B7 
substrates. Therefore, the physiological and physicochemical 
basis of this semiphysiological glucuronidation function was 
investigated using PKPB modeling software (Simcyp, Shef-
field, UK). Investigation of the influence of system-specific 
and drug-specific parameters revealed that increases in liver 
volume and UGT2B7 ontogeny are the physiological drivers 
of the developmental changes in in vivo drug glucuronida-
tion (Table 1 and  Figure 2). Concerning physicochemical 
drug characteristics, the log P and pK
a
 of a drug, but not the 
molecular mass, were found to influence the absolute value of 
glucuronidation, without influencing the maturation pattern.
Figure 1 shows that the clearance predictions by the 
PBPK model (symbols), using available in vitro information 
on UGT2B7 enzyme kinetics of morphine and zidovudine, 
are generally lower than the clearance values obtained in the 
population models with the semiphysiological glucuronida-
tion function. In addition, Figure 2 shows that the combined 
influence of the age-related increases in the system-specific 
parameters investigated in this study (solid black line) does 
not fully explain the clinically observed increase in morphine 
and zidovudine clearance (solid gray line), not even when the 
rapid increase in glucuronidation described by the semiphysi-
ological glucuronidation function at 10 days after birth is dis-
carded (dashed gray line). These discrepancies are probably 
the result of a combination of factors:
First, the uridine 5′-diphosphate glucuronisyltransferase 
enzyme kinetic parameters for morphine and zidovudine were 
obtained from studies using liver microsomes. Confidence 
that these values accurately represent in vivo enzyme kinet-
ics is limited by various factors that influence these measured 
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Figure 2 Developmental changes in in vivo morphine and zidovudine clearance in the first 3 years of life relative to birth. The solid gray 
line represents the total increase according to the population models using the semiphysiological glucuronidation function and the  dotted 
gray line represents the clearance increase according to these models without taking the rapid increase at the age of 10 days into 
account. The solid black line represents the sum of the changes by all five system-specific parameters with the non-solid black lines 
 representing the individual contribution of each system-specific parameter.
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in vitro values causing difficulties in obtaining good predictions 
on in vivo UGT enzyme kinetics from microsome studies.5–9 In 
fact, in this study, the reported K
m
 values had to be adjusted 
to values that yielded accurate clearance predictions by the 
PBPK model in adults. In a sensitivity analysis, increasing and 
decreasing V
max
 and K
m
 values by 10-fold yielded predicted 
pediatric glucuronidation clearances that changed by a factor 
of 2 for M6G formation and a factor of 12 for both zidovudine 
glucuronidation and M3G formation. It is, however, emphasized 
that bias in enzyme kinetic parameter values obtained in vitro 
limits the predictions of absolute glucuronidation clearance by 
the PBPK model but not the maturation pattern.
Additional discrepancies may be the result of the assump-
tion in the PBPK model that morphine and zidovudine were 
solely eliminated through UGT2B7-mediated glucuronida-
tion, whereas some studies have suggested that morphine 
is, to a small degree, also eliminated through sulfation or 
unchanged elimination in the very young.10,11 Moreover, active 
drug uptake or efflux by hepatocytes and biliary clearance of 
morphine and zidovudine were assumed to be zero. Whereas 
animal studies with morphine have shown energy-dependent 
carrier-mediated uptake of morphine in hepatocytes,12,13 
other studies found active hepatic uptake to not limit hepatic 
morphine metabolism.14 Finally, biliary clearance of morphine 
was reported in rat livers.14
Furthermore, concerning the system-specific parameters 
in the PBPK model, while the maturational changes in liver 
volume are based on a large number of observations,15 the 
pediatric information on other system-specific parameters is 
more limited, decreasing the level of confidence in the ontog-
eny profiles of these parameters. In particular, the UGT2B7 
expression and function in the PBPK model increases linearly 
with age from 8.9% from adult values at birth to adult val-
ues at the age of 20 years. Literature data, however, suggest 
the expression and function of UGT isoenzymes to increase 
rapidly in the first few weeks of life.16 Given that morphine 
and zidovudine clearances were found to be sensitive to 
changes in the UGT2B7 ontogeny, a suboptimal represen-
tation of this ontogeny profile may explain the discrepancy 
in the morphine and zidovudine clearance values (Figure 1) 
and the discrepancy between the increases in morphine 
and zidovudine clearances in (Figure 2). As liver volume 
and UGT2B7 ontogeny are the main drivers of UGT2B7-
m ediated glucuronidation and as the maturation profile of 
liver volume is well established,15 an improved function for 
UGT2B7 ontogeny in the PBPK model can be obtained by 
subtracting the maturation function for liver volume from the 
semiphysiological glucuronidation function in children. As 
such, pediatric population PK modeling, which is based on 
in vivo outcome measures, can indeed provide maturation 
functions for pediatric PBPK models.
Concerning drug characteristics, the molecular weight of 
hypothetical drugs was not found to influence drug glucuroni-
dation, whereas the log P and pK
a
 of the hypothetical drug 
molecule influenced only the absolute value of glucuronida-
tion, which is reflected in the population clearance value. 
These results thereby support the hypothesis that this 
value is drug specific. Since in a semiphysiological model-
ing approach for new UGT2B7 substrates the value of this 
constant is estimated based on the population analysis of 
outcome measures, these results suggest that the semiphys-
iological glucuronidation function can predict developmental 
changes in glucuronidation clearance of all small-molecular 
substrates for UGT2B7.
A relevant question in this context is whether the semiphysi-
ological glucuronidation function can be applied to drugs with 
saturable kinetics. In this study, a linear relationship was found 
between unbound drug concentration in plasma and the abso-
lute value of glucuronidation; however, the Michaelis–Menten 
parameters were kept constant in each simulation. Michaelis–
Menten parameters influence drug metabolism significantly, 
but due to the nonlinear correlation between substrate concen-
tration and intrinsic drug clearance, interpretation of the results 
from simulations with varying Michaelis–Menten constants is 
complex. We, therefore, conclude that further simulations with 
varying Michaelis–Menten constants are necessary to investi-
gate the applicability of the semiphysiological glucuronidation 
function to drugs with saturable kinetics.
In addition, the application of the semiphysiological 
glucuronidation function in scenarios of drugs with varying 
extraction ratios needs further investigation. The ontogeny of 
UGT2B7 isoenzymes may have a one to one effect on low-
extraction substrates as in this case, in vivo clearance closely 
reflects intrinsic clearance. By contrast, high-extraction sub-
strates may be affected less by an increased level in UGT 
activity as their clearance is limited by hepatic blood flow. 
With similar extraction ratios of morphine and zidovudine 
of 0.5 and 0.65, respectively,17–19 the influence of changes 
in the underlying physiological system is expected to be 
rather similar for both drugs, resulting in the same ranking 
of system-specific parameters in Table 1 and the possibility 
to extrapolate the semiphysiological glucuronidation function 
between these drugs (see Part I of this article, ref. 1). The 
small difference in extraction ratio that does exist between 
these two drugs may explain why the influence of hepatic 
blood flow on in vivo clearance is more pronounced for zido-
vudine than for morphine.
In conclusion, direct extrapolation of the pediatric covariate 
model in a semiphysiological modeling approach as described 
in Part I of this article1 is possible between UGT2B7 sub-
strates that have linear kinetics and similar extraction ratios. 
The relatively large impact of changes in liver volume on in 
vivo drug glucuronidation suggest that the applicability of the 
semiphysiological glucuronidation function in patients with a 
decreased liver size or liver function may be reduced. The 
currently available maturation profile for UGT2B7 ontogeny 
in the PBPK model can be improved based on information 
obtained in the covariate model of a pediatric population 
model.
METHODS
PBPK simulations. Simcyp version 11 (Simcyp, Sheffield, UK) 
was used to investigate the influence of system-specific and 
drug-specific parameters on the ontogeny of in vivo UGT2B7-
mediated drug glucuronidation in the first 3 years of life (see 
Part I of this article, ref. 1). The pediatric database was selected 
for the simulations and parameters were set to include patients 
CPT: Pharmacometrics & Systems Pharmacology
Physiological and Physicochemical Properties of a Paediatric Covariate Model 
Krekels et al
6
with a maximum age of 3 years. The accuracy of pediatric clear-
ance predictions for 11 drugs by the Simcyp software package 
was illustrated previously.20 A total of 1,000 individuals were 
simulated and the same random number generation seed was 
used for repeated simulations, yielding the same set of indi-
viduals for each simulation, allowing for a direct comparison of 
clearance predictions between individuals in simulations with 
varying parameter values. A uniform age distribution was used 
and the male/female ratio was set to 1. For each of the 1,000 
simulated individuals, age- and sex-appropriate bodyweight 
and height were determined based on UK reference growth 
charts taking interindividual variability into account.21 The par-
allel-tube model was used to derive whole blood hepatic drug 
clearances from intrinsic hepatic clearance, hepatic blood flow, 
and the unbound drug fraction in blood.
Morphine and zidovudine were used as model compounds 
as both drugs are specific substrates for the UGT2B7 isoen-
zyme22–24 and used in the proof-of-concept studies for the 
development of the semiphysiological glucuronidation func-
tion (see Part I of this article, ref. 1). In the simulations, clini-
cally relevant intravenous bolus doses of 0.1 mg/kg morphine 
or 3 mg/kg zidovudine were administered.
System-specific parameters. The pediatric database in 
Simcyp is based on system-specific parameter values and 
variability measures in these parameters that represent a 
“healthy” population. Simulations in this population form the 
basis for exploring the influence of changes in the system-
specific parameters that can be the result of not only matura-
tion but also disease.
Hepatic blood flow, liver volume, milligram protein per gram 
of liver, UGT2B7 ontogeny, and unbound drug fraction were the 
system-specific parameters that were investigated. “UGT2B7 
ontogeny” denotes the fractional expression and function of the 
UGT2B7 isoenzyme in children as compared with adults. The 
percentage change of each of the parameters was obtained by 
calculating the mean parameter value of all individuals with an 
age in the first 2 weeks and the last 2 weeks of each interval 
and by determining the percentage increase in these values 
per group for the patients in the following groups: I, the first 
3 months of life (0–3 months); II, the second 3 months (3–6 
months); III, the second half year (6–12 months); IV, the sec-
ond year (1–2 years); and V, the third year (2–3 years).
Subsequently, one at a time, the values of each system-
specific parameter were increased with a physiologically rele-
vant value based on the mean increase in each age group. For 
hepatic blood flow and liver volume, the value was 23%, for 
milligram protein per gram of liver it was 2%, for the UGT2B7 
ontogeny profile, 21%, and for the unbound drug fraction, the 
values were 0.51% for morphine and 0.33% for zidovudine. 
As the user cannot alter the UGT2B7 ontogeny profile in the 
Simcyp software, an alternative scenario was simulated to 
represent an increase of 21% in the UGT2B7 ontogeny pro-
file. The age-appropriate ontogeny factor for each individual, 
which is derived from the ontogeny profile, is a scalar for the 
intrinsic glucuronidation clearance that takes place in both 
the liver and the kidneys. Similarly, liver density is a scalar 
for intrinsic UGT2B7-mediated glucuronidation in the liver, 
whereas milligram microsomal protein per gram of kidney 
is a scalar of intrinsic UGT2B7-mediated glucuronidation 
clearance in the kidney. Therefore, simulation of a scenario in 
which both liver density and milligram microsomal protein per 
gram of kidney are increased by 21% were used to represent 
a situation with a 21% increased UGT2B7 ontogeny profile.
To quantify the influence of these physiologically relevant 
changes in the system-specific parameters on the predicted in 
vivo clearance, a sensitivity ratio was calculated for each indi-
vidual. For this sensitivity ratio, the difference in in vivo clear-
ance predictions was divided by the percentage difference in 
the system-specific parameter. Mean sensitivity ratios were 
calculated for each system-specific parameter in each of the 
age groups. By multiplying the percentage change in a system-
 specific parameter in each age group by the mean sensitiv-
ity ratio for that age group, the percentage change in in vivo 
glucuronidation clearance as a result of the changes in the 
underlying parameter value in that age range was determined.
Drug-specific parameters. Morphine and zidovudine were 
added to the compound database in Simcyp by obtaining their 
drug-specific parameters from the literature. In all simulations, 
the assumption was made that there is no elimination through 
pathways other than UGT2B7-mediated glucuronidation, that 
there is no active drug transport into or out of the hepatocytes, 
and that there is no biliary clearance. Inclusion of these pro-
cesses would increase the predicted drug clearance.
The obtained drug-specific parameters for each drug are 
presented in Table 2. With respect to the Michaelis–Menten 
parameters, values for the formation of the two morphine 
glucuronides were obtained from the liver microsomes from 
five separate adults25
 and values for the glucuronidation of 
zidovudine were obtained from the liver microsomes from 
four adults.26 To verify the obtained drug-specific parameters, 
predictions of morphine and zidovudine clearances for 1,000 
healthy adult volunteers were compared with reported clear-
ance values in adults of 93 l/h for morphine27–29 and 91.2 l/h 
for zidovudine.30–32 This yielded a 75% mean underprediction 
for morphine and a 71% mean underprediction for zidovu-
dine. On the basis of the literature reports that show that for 
UGTs albumin and fatty acids in in vitro assays influence K
m
 
values but not V
max
 values,5,6 the clearance predictions for 
morphine and zidovudine in adults were optimized by adjust-
ing the K
m
 values. For morphine, the optimized K
m
 value was 
115.8 μmol/l for the formation of both M3G and M6G, and for 
zidovudine this was a value of 4 μmol/l. These values were 
subsequently used in the pediatric simulations.
To identify how physicochemical drug properties influence 
the maturation pattern of UGT2B7-mediated glucuronida-
tion, in vivo clearance values of hypothetical UGT2B7-specific 
substrates with physicochemical properties that are com-
mon for small-molecular drugs were simulated with Simcyp. 
In these simulations, the implicit assumption was made that 
the changes in physicochemical properties influenced neither 
the active transport of the hypothetical drug into or out of the 
hepatocytes nor the interaction of the hypothetical drug with 
the UGT2B7 isoenzyme. Hypothetical drugs with molecular 
weights of 100, 200, 500, 800, and 1,000 g/mol were simu-
lated in combination with log P values of 0.01, 1, and 5.5. Neu-
tral compounds were simulated as well as monoprotic acids 
and bases with pK
a
 values of 2 or 5 and 8.5 or 12, respec-
tively, and diprotic acids and bases with pK
a
 values of 2 and 5 
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and 8.5 and 10, respectively. An ampholyte was used with a 
pK
a
 of 5 and 9. These values are summarized in Table 2. The 
Simcyp toolbox was used to calculate the blood/plasma ratio 
and unbound drug fraction for each hypothetical drug based 
on log P and pK
a
 values. The Michaelis–Menten parameters 
obtained for morphine were used, and in the simulations an 
intravenous drug dose of 0.1 mg/kg was administered.
The influence of changes in physicochemical drug param-
eters on the predicted in vivo clearance was assessed by 
changing one parameter value at a time and calculating the 
percentage difference between the clearance predictions 
between two simulations. When the highest individual pre-
diction difference was <5%, the parameter was classified as 
not significantly influencing drug glucuronidation. When the 
highest individual prediction difference was >5% and the dif-
ference between mean prediction difference of individuals in 
the first month of life and individuals in the 35th month of 
life was <5%, a parameter was classified as influencing the 
absolute value of drug glucuronidation. When the difference 
between mean prediction difference of individuals in the first 
month of life and individuals in the 35th month of life was 
>5%, the parameter was classified as influencing the ontog-
eny profile in addition to influencing the absolute value of 
drug glucuronidation clearance.
Semiphysiological glucuronidation function. The semiphysi-
ological glucuronidation function is obtained from a pediatric 
population covariate model quantifying the net observed matu-
rational changes in drug glucuronidation clearance in children 
younger than the age of 3 years including preterm and term 
neonates. This model was obtained and validated in a popula-
tion analysis of pediatric morphine data3,4 and could also be 
directly extrapolated to zidovudine (see Part I of this article, 
ref. 1). In this model, the overall developmental changes in 
drug glucuronidation in children younger than 3 years are 
quantified according to Eq. 1:
(1)
in which CLind represents the individual glucuronidation clear-
ance, CLpop represents the population clearance, fneonate<10 
represents a reduced glucuronidation fraction in neonates 
younger than 10 days, and BW represents the bodyweight 
of an individual pediatric patient in kilograms. The popula-
tion clearance for each drug was estimated from clinical out-
come measures in a population analysis. The reduction in 
glucuronidation clearance in neonates with a postnatal age 
younger than 10 days (f
neonate<10) is 50% and is independent 
from gestational age. The final element of Eq. 1 quantifies the 
overall ontogeny of in vivo drug glucuronidation in this young 
population using bodyweight as a surrogate descriptor in an 
exponential equation with an exponent of 1.44.
Using available in vitro data as input parameters, the mor-
phine and zidovudine clearance predictions by the physi-
ologically based PK model in Simcyp were compared with 
the clearance values according to the population models 
using the semiphysiological glucuronidation function. This 
was done by plotting clearance values from these models vs. 
bodyweight, which is the primary covariate in the semiphysio-
logical glucuronidation function, and by plotting the prediction 
difference between these clearance values for each drug for 
each of the 1,000 simulated individuals vs. bodyweight.
In addition, for each simulated individual in this study, the mor-
phine and zidovudine clearances according to the population 
models using the semiphysiological function were determined 
as well. The percentage increase in morphine and zidovudine 
clearance values in each of the five age groups according to 
these models were calculated as described above and com-
pared with the increase in morphine and zidovudine clearances 
predicted by the PBPK model for each age group.
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